Trump threatens pharmaceutical tariffs of 200%
US President Donald Trump during a cabinet seat in the White House in Washington, DC, USA, on Tuesday, July 8, 2025.
Aaron Schwartz | Bloomberg | Getty pictures
On Tuesday, President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals that were “very soon” imported into the USA.
“You will z.
But he suggested that these taxes would not come into force immediately, and said that he would give people “about a year and a half, half years”.
“We will give you a certain time to put together your action”
Details on pharmaceutical tariffs “will take place at the end of the month,” said Minister of Commerce Howard Lutnick after the cabinet seats to CNBC.
“With pharmaceuticals and semiconductors, these studies will be completed at the end of the month, and so the president will then determine his guidelines, and I will let him wait to decide how to do it,” said Lutnick.
The president repeatedly threatened and then changed the course for tariff proposals, so there is no guarantee that he will use pharmaceutical tariffs to 200%. According to Trump's comments, the pharmaceutical stocks were largely unchanged.
In a note on Tuesday, the analyst of Leerink Partners said David Risinger said that he was positive for the announcement for the industry, “because the tariffs are not implemented immediately … and it is unclear whether the administration will go through in the future.”
It has been Trump's most important comment on pharmaceutically specific tariffs since April when his administration initiated a so -called examination of section 232 for these products. This legal authority allows the trade knowledge to examine the effects of imports on national security.
These planned tariffs would affect the pharmaceutical company a long -awaited blow, many of which have pushed back, and warned that the taxes increase the costs, deter investments in the USA and disturb the pension chain of medicinal products that endanger the patients. The industry is already navigating through Trump's drug price guidelines that claim drug manufacturers both their profit size and their ability to invest in research and development.
Trump stated Eli LillyPresent Johnson & JohnsonPresent Abbvie And others are already putting more money into the USA after the production of domestic medications has shrunk dramatically in recent decades.
Phrma, the largest lobby group in the United States, repeated an earlier explanation that pushes back the pharmaceutical tariffs.
“Every dollar spent on tariffs is a dollar that cannot be invested in the American production or development of future treatments and remedies for patients,” said Alex Schriver, Senior Vice President of Public Affairs at Phrma.
“The industry shares the goal of President Trump to revitalize American production and recently announced hundreds of billions of dollars of US investments, but to place the tariffs for medicines for these efforts,” he continued. “Medicines were historically freed from tariffs because they can increase the costs and lead to bottlenecks.”
